Tech Center 1600 • Art Units: 1691
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17998512 | COMPOUND FOR PREVENTING OR TREATING A VIRAL INFECTION | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 19177218 | TERTIARY AMIDE DERIVATIVES SUBSTITUTED WITH 4-MEMBERED RING STRUCTURE | Final Rejection | NATIONAL CANCER CENTER |
| 18002710 | PanK Modulators and Methods Using Same | Non-Final OA | YALE UNIVERSITY |
| 18990537 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18253891 | COMPOSITIONS AND METHODS FOR BLOCKING NEUROPILIN RECEPTOR 1 FOR THE TREATMENT OF PAIN AND PREVENTION OF VIRAL ENTRY | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18021320 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18134770 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | Non-Final OA | The Chinese University of Hong Kong |
| 18297439 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Final Rejection | National Yang Ming Chiao Tung University |
| 18454796 | APPLICATION OF RILUZOLE IN TREATMENT OF OLIGOSPERMIA | Non-Final OA | Jinan University |
| 18041262 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | Non-Final OA | ALBERT EINSTEIN COLLEGE OF MEDICINE |
| 18030518 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Non-Final OA | VERTEX PHARMACEUTICALS INCORPORATED |
| 17318921 | THE USE OF CHOLINE SUPPLEMENTATION AS THERAPY FOR APOE4-RELATED DISORDERS | Non-Final OA | Whitehead Institute for Biomedical Research |
| 17823793 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Non-Final OA | Omeros Corporation |
| 18254374 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | Non-Final OA | Xizang Haisco Pharmaceutical Co., Ltd. |
| 18455098 | VAFIDEMSTAT FOR USE IN TREATING AUTISM SPECTRUM DISORDERS | Non-Final OA | ORYZON GENOMICS, S.A. |
| 18185193 | CDK Inhibitors And Their Use As Pharmaceuticals | Non-Final OA | Prelude Therapeutics, Incorporated |
| 17926763 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Final Rejection | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| 18270616 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Non-Final OA | Tabomedex Biosciences, Inc. |
| 18268957 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | Final Rejection | SHANGHAI KECHOW PHARMA, INC. |
| 18302615 | BICYCLIC COMPOUNDS | Non-Final OA | Aligos Therapeutics, Inc. |
| 18019792 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | Non-Final OA | ELLIPSES PHARMA LTD |
| 17936089 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Non-Final OA | Engine Biosciences Pte. Ltd. |
| 17769518 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Non-Final OA | Kinesid Therapeutics, Inc |
| 17438825 | SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES COMPRISING AN MTOR INHIBITOR AND ALBUMIN FOR TREATMENT OF DISEASES | Final Rejection | Abraxis BioScience, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy